BioCurex, Inc.(fka BOCX)

[dakota]

and lastly, this.

"We determined that a colorimetric blood test using RECAF for cancer detection would be simpler to use and more readily shipped to various labs and companies than our current test that employs low doses of radioactivity. The improvements resulting from this work have magnified the measured differences in serum values for RECAF between normal and cancer patients. This large difference between cancers and normal patients not only allows the detection of smaller tumors, (as recently shown for breast cancers where we can now detect 90% of early stages I and II); but it is also a requirement for a "yes/no" rapid test similar to a pregnancy test that could be used directly in the doctors' offices."